Positive topline results for SAR 1118 (SARcode) for treating Dry Eye Disease

Topline results from OPUS-1, a pivotal Phase III study of SAR 1118 (lifitegrast ophthalmic solution), from SARcode, for the treatment of Dry Eye Disease demonstrate the drug is superior to placebo in the improvement of inferior and total corneal staining scores from baseline to week 12. Lifitegrast also significantly improved the most commonly reported symptoms of dry eye disease in the study, which were ocular discomfort and eye dryness. The mean ocular discomfort score and mean eye dryness score were lower in the lifitegrast group than in the placebo group at week 12. Lifitegrast was well tolerated and there were no unexpected or serious ocular adverse events. SARcode Bioscience recently commenced a year-long safety study (SONATA) and will soon begin a second pivotal Phase III confirmatory study (OPUS-2). Both studies will support a planned New Drug Application filing.